Full-Time

Vice President

Medical Affairs

Posted on 12/20/2024

Kymera Therapeutics

Kymera Therapeutics

201-500 employees

Develops targeted protein degradation therapies

Biotechnology
Healthcare

Expert

Belmont, MA, USA

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • Medical Doctorate (MD) degree required and either PhD and/or MBA preferred.
  • Minimum of 15 years of pharmaceutical/biotechnology industry experience working in both US and global markets with at least 10 years in immunology/inflammation in Medical Affairs or closely aligned roles.
  • At least 5 years of experience leading immunology/inflammation Medical Affairs teams.
  • Direct experience working within complex global alliance/partnership environment.
  • Experience working with BD teams and providing medical affairs insights during business development and licensing.
  • Extensive hands-on experience in immunology/inflammation with a focus on developing/implementing medical affairs strategy and integrated evidence generation plans.
  • Deep experience working with US and global commercial teams, reimbursement, and sales functions.
  • Strong business acumen and understanding of immunology/inflammation market dynamics and key value drivers.
  • Solid understanding of clinical trial design, global drug development, regulatory approval process, early access programs, ACCME guidelines, and registry implementation to support the US and global launches and HTA submission.
  • Demonstrated knowledge of implementing latest digital channels/tools to optimize and expand reach and frequency of interactions with US providers, advocacy organizations, patients, and key partners.
  • Direct knowledge of promotional regulatory processes, Fair Market Value (FMV) process, tiering, and alignment with third-party vendors.
  • Willingness to roll-up sleeves and be hands-on.
Responsibilities
  • Leads a high-functioning, stage-appropriate US Medical Affairs organization to include in-house and field Medical Science Liaisons (MSLs), and other appropriate functions, such as scientific communications, evidence generation, and professional society/advocacy engagement.
  • Oversee all aspects of Medical Affairs strategic/operational/tactical plans, budgets, and processes, including Field Medical activities, patient advocacy, provision of medical information upon unsolicited request, CME/grants/medical sponsorships, and field IT requests.
  • Ensures compliant and medically appropriate metrics are designed, implemented, and followed by the therapeutic field-based MSLs.
  • Ensure compliance with regulatory requirements and industry standards.
  • Collaborate with clinical development, regulatory affairs, and leadership to support product launch activities.
  • Monitor and analyze emerging trends in immunology/inflammation to inform strategic decision-making.
  • Support the Corporate Strategy and Business Development functions by providing Medical Affairs input for consideration for future business opportunities.

Kymera Therapeutics develops treatments by targeting and breaking down specific proteins that contribute to diseases, particularly cancer and immune disorders. Their main technology, the Pegasus Platform, enables them to identify these harmful proteins and create drug candidates aimed at effectively treating various conditions. Unlike many competitors, Kymera focuses on targeted protein degradation, which can lead to more precise therapies. The company's goal is to create next-generation medicines that address unmet medical needs, supported by partnerships with organizations like Sanofi to advance their research and development efforts.

Company Stage

IPO

Total Funding

$191.6M

Headquarters

Cambridge, Massachusetts

Founded

2016

Growth & Insights
Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

15%
Simplify Jobs

Simplify's Take

What believers are saying

  • Kymera's $225M and $275M offerings indicate strong investor confidence and capital availability.
  • Partnership with Neosphere Biotechnologies boosts molecular glue target discovery opportunities.
  • HSBC's investment reflects strong financial backing and future growth potential.

What critics are saying

  • Increased competition from Arvinas and Nurix may impact Kymera's market share.
  • Reliance on public offerings for funding poses long-term financial sustainability risks.
  • Regulatory scrutiny could delay clinical trials and drug approval timelines.

What makes Kymera Therapeutics unique

  • Kymera's Pegasus Platform uniquely targets and degrades disease-causing proteins.
  • The company focuses on innovative treatments for cancer and immune disorders.
  • Kymera's strategic partnership with Sanofi enhances its position in the pharmaceutical ecosystem.

Help us improve and share your feedback! Did you find this helpful?